Hansen Tobias N, Yuan Xinyi, I Santana Marc S, Olsen Christian A
Center for Biopharmaceuticals & Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100 Copenhagen, Denmark.
Center for Biopharmaceuticals & Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100 Copenhagen, Denmark.
Bioorg Med Chem Lett. 2025 Jan 1;115:130017. doi: 10.1016/j.bmcl.2024.130017. Epub 2024 Nov 7.
Sirtuin 5 (SIRT5) is a lysine deacylase enzyme that cleaves negatively charged ε-N-acyllysine posttranslational modifications, arising from short dicarboxylic acids. Inhibition of SIRT5 has been suggested as a target for treatment of leukemia and breast cancer. In this work, we performed a focused structure-activity relationship study that identified highly potent inhibitors of SIRT5. Examples of these inhibitors were shown by kinetic evaluation to function as mechanism-based inactivators. Masking of a crucial carboxylate functionality in the inhibitors provided prodrugs, which were demonstrated to bind SIRT5 in cells. This work underscores the importance of kinetic characterization of enzyme inhibitors and provides insights for the further optimization of inhibitors of SIRT5 with potential for in vivo applications.
沉默调节蛋白5(SIRT5)是一种赖氨酸脱酰酶,可切割由短二羧酸产生的带负电荷的ε-N-酰基赖氨酸翻译后修饰。抑制SIRT5已被提议作为治疗白血病和乳腺癌的靶点。在这项工作中,我们进行了一项重点结构-活性关系研究,确定了SIRT5的高效抑制剂。通过动力学评估表明,这些抑制剂的实例可作为基于机制的失活剂发挥作用。抑制剂中关键羧酸盐官能团的掩蔽产生了前药,已证明这些前药可在细胞中与SIRT5结合。这项工作强调了酶抑制剂动力学表征的重要性,并为进一步优化具有体内应用潜力的SIRT5抑制剂提供了见解。